How to choose an NIH institute for an SBIR application

Most founders pick an NIH institute the way they pick a journal, by topic. A pain device goes to NINDS, an imaging tool goes to NIBIB, a cancer diagnostic goes to NCI. That is a reasonable first guess and a poor final answer, because the institute that reviews your application also sets the payline that decides whether it is funded. The spread between institutes is large enough to double or halve your odds before a reviewer reads a word.

The FY2024 numbers

SBIRLand compiled institute level success rates from NIH RePORTER for fiscal year 2024. The institutes most relevant to a bioelectronic pain device are in bold, but the pattern holds for any technology that could plausibly be reviewed by more than one institute.

Source: SBIRLand, SBIR and STTR success rates by institute, compiled from NIH RePORTER. The authoritative tables are downloadable from NIH RePORT success rates and the NIH Data Book, report 96.

Read the first two rows against the fifth. The two obvious homes for a chronic pain device, NINDS and NIBIB, funded 5 to 6 percent of SBIR Phase I applications in FY2024. NIDA, which funds HEAL Initiative work on non opioid pain management, funded 28 percent. NCCIH, which covers nonpharmacologic pain approaches, funded 14 percent. The same device with the same data faces a fivefold difference in base rate depending on where it lands.

The NIH wide trend makes this worse, not better. A RePORTER derived summary reports that NIH SBIR success rates fell from 31 percent in 1998 to 12 percent in 2024, with Phase I falling from 28 percent to 10 percent and Phase II from 49 percent to 18 percent (Substack note citing NIH data). A consultant aggregator gives a three year NIH Phase I average of 15 to 18 percent through FY2025 (Granted AI). When the average is 12 percent, the difference between a 5 percent institute and a 28 percent institute is the whole game.

Why the rates differ

Three things drive the spread.

Budget and volume. Each institute funds SBIR from a set aside of its own appropriation. An institute with a large budget and a small business community that is thin relative to it, such as NIDA in the years HEAL money flowed, has more awards per applicant. An institute with an enormous applicant pool, such as NCI, is crowded.

Paylines and priorities. Consultants report effective SBIR paylines of under 30 at NINDS, under 29 at NIBIB, around 26 at NIAMS, and under 55 at NIDA (Grant Engine). These are unofficial and NIH does not publish them, but they match the RePORTER outcome data. An impact score of 35 is a rejection at NIBIB and a likely award at NIDA.

Programmatic fit. Program officers make funding decisions above and below the payline based on how well the project matches the institute’s stated priorities. A pain device framed as an opioid alternative is squarely within NIDA’s HEAL mandate. The same device framed as a neural engineering advance is one of hundreds at NINDS.

What reviewers score, and what they do not

A second widely misunderstood point. NIH’s Simplified Review Framework, with its three factors of Importance, Rigor and Feasibility, and Expertise and Resources, does not apply to SBIR and STTR. NOT-OD-25-116 lists the covered activity codes for due dates on or after January 25, 2025, and R41, R42, R43, and R44 are absent. SBIR applications continue to be scored on the five classic criteria with small business specific questions from the omnibus, PA-24-245: Significance, Investigators, Innovation, Approach, and Environment, with each criterion scored 1 to 9 and the overall impact score being the average times 10.

Secondary sources give these fundability bands: 10 to 20 almost always funded, 21 to 30 funded at most institutes, 31 to 40 depends on the institute and its payline, 41 to 50 unlikely without resubmission, 51 and above needs restructuring. The bottom half of applications are not discussed and receive no score (SBIR Grant Writers summary statement guide). Notice that the middle band, 31 to 40, is exactly where institute choice decides the outcome.

How to influence assignment

You do not get to pick your institute outright, but you get a strong say.

1. Use the PHS Assignment Request Form. It is part of the application package. Name your preferred institute and, if useful, a secondary. Name the study section you believe is appropriate. Reviewers and referral officers read it.
2. Talk to program officers early. Send a two paragraph project summary to the relevant institute’s small business program officer two to three months before the deadline. Ask about fit, waiver topics, and institute specific priorities (NC SBTDC guide to the September 5 deadline). NINDS publishes named contacts for translational neural devices, clinical and research tools, and drug development (NINDS small business areas of interest). Talk to more than one institute. For a pain device that means NIDA and NCCIH, not only NINDS.
3. Use RePORTER Matchmaker. Paste your abstract into the NIH RePORTER Matchmaker tool and it returns the institutes and study sections that funded similar work (NIDA SBIR resources). This is evidence, not opinion, and it belongs in your assignment request.
4. Frame for the institute. The title, the abstract, and the first paragraph of the Specific Aims page determine referral. If you want NIDA, the words non opioid, opioid sparing, and HEAL belong in the first hundred words. If you want NCCIH, nonpharmacologic and complementary approach belong there.

Worked example

Take a Direct to Phase II application for a neuromodulation device with a completed randomized trial. Our research report’s rubric produces a fit score of 75 for the HEAL aligned framing. Anchored to the NIDA Phase II base rate of 21 percent and multiplied by the fit curve, the win probability comes to about 0.32, which we cap at 0.30 as a matter of judgment. With a $2.15 million award, 90 percent usable, $60,000 to apply, and $120,000 of compliance cost over the award, the expected value is roughly plus $485,000.

The same application assigned to NINDS, with its 9.7 percent Phase II base rate, gives a win probability of about 0.15 and an expected value of about plus $185,000. Still positive, but less than half. Nothing about the science changed. Only the institute did.

We walk through that arithmetic in Expected value math for grant applications.

Where this lives in epiensos

Every match card in epiensos shows the base rate for the institute and phase the opportunity would be reviewed under, and the scoring rubric weights base rate at 15 of 100 points. When a notice could be assigned to more than one institute, the rationale names the alternatives and the difference in expected value. The application checklist includes the PHS Assignment Request Form and a task to contact each candidate institute’s program officer at least eight weeks before the due date. When the outcome comes back, the TALR learn step records which institute reviewed it and what the impact score was, so the next Think step starts from evidence instead of habit.

Practical notes for FY2026 and FY2027

The FY2026 omnibus reissue, PA-27-100, is reported to raise the caps to $323,090 for Phase I and $2,153,927 for Phase II, add a Commercialization Readiness Pilot up to $4,191,495, and introduce a Phase IIB Strategic Breakthrough Award up to $30 million with 100 percent matching (Minnesota SBIR summary of FY2026 NIH solicitations, Granted AI on PA-27-101). It also limits each company to nine SBIR and STTR submissions per fiscal year, requires ORCID for all senior and key personnel, and offers no late submission accommodation for small businesses. Standard due dates remain September 5, January 5, and April 5. Read the notice on grants.nih.gov before quoting any of these, since secondary sources disagree on the Phase I ceiling.

Repeat applicants win at roughly 1.3 to 1.5 times the rate of first time applicants across agencies (Granted AI). If your first application lands at the wrong institute and scores in the thirties, the resubmission with a better assignment request is often the one that funds.